Current status of antiretroviral therapy

被引：60

作者：

Temesgen, Zelalem ^{[1
]}

Warnke, David ^{[1
]}

Kasten, Mary J. ^{[1
]}

机构：

[1] Mayo Clin & Mayo Fdn, Div Infect Dis, Rochester, MN 55905 USA

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2006年 / 7卷 / 12期

关键词：

antiretrovirals; antiretroviral therapy; chemokine receptor antagonists; entry inhibitors; fusion inhibitors; highly active antiretroviral therapy; HIV; integrase inhibitors; maturation inhibitors; non-nucleoside analogue reverse transcriptase inhibitors; nucleoside analogue reverse transcriptase inhibitors; protease inhibitors; treatment guidelines;

D O I：

10.1517/14656566.7.12.1541

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

At present, there are 22 FDA-approved antiretroviral agents, which are categorised into four classes of drugs. Several others are in various stages of basic and clinical development. The authors of this paper review the general characteristics of each class of antiretrovirals, as well as individual investigational agents that are in advanced clinical development. A brief synopsis of US and WHO antiretroviral treatment guidelines is also provided.

引用

页码：1541 / 1554

页数：14

共 54 条

[1] Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs [J].

Ananworanich, J ;

Moor, Z ;

Siangphoe, U ;

Chan, J ;

Cardiello, P ;

Duncombe, C ;

Phanuphak, P ;

Ruxrungtham, K ;

Lange, J ;

Cooper, DA .

AIDS, 2005, 19 (02) :185-192

[2] Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine [J].

Barrios, A ;

Rendón, A ;

Negredo, E ;

Barreiro, P ;

Garcia-Benayas, T ;

Labarga, P ;

Santos, J ;

Domingo, P ;

Sánchez-Conde, M ;

Maida, I ;

Martín-Carbonero, L ;

Núñez, M ;

Blanco, F ;

Clotet, B ;

Sambeat, MA ;

Gil, P ;

Gonzalez-Lahoz, J ;

Cooper, D ;

Soriano, V .

AIDS, 2005, 19 (06) :569-575

[3]

BARTLETT JA, 2002, 14 INT AIDS C JUL 7

[4]

BEATTY G, 2005, 45 INT C ANT AG CHEM

[5] HIV-1 cell entry and advances in viral entry inhibitor therapy [J].

Cooley, LA ;

Lewin, SR .

JOURNAL OF CLINICAL VIROLOGY, 2003, 26 (02) :121-132

[6]

COTE H, 2005, 3 IAS C HIV PATH TRE

[7] HIV integrase, a brief overview from chemistry to therapeutics [J].

Craigie, R .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (26) :23213-23216

[8] Periconceptional exposure to efavirenz and neural tube defects [J].

De Santis, M ;

Carducci, B ;

De Santis, L ;

Cavaliere, AF ;

Straface, G .

ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (03) :355-355

[9] Mechanisms of viral membrane fusion and its inhibition [J].

Eckert, DM ;

Kim, PS .

ANNUAL REVIEW OF BIOCHEMISTRY, 2001, 70 :777-810

[10] Effect of tenofovir on didanosine absorption in patients with HIV [J].

Fulco, PP ;

Kirian, MA .

ANNALS OF PHARMACOTHERAPY, 2003, 37 (09) :1325-1328

← 1 2 3 4 5 6 →